EP2247306B1 - Lutte par voie immunogène contre les tumeurs et cellules tumorales - Google Patents
Lutte par voie immunogène contre les tumeurs et cellules tumorales Download PDFInfo
- Publication number
- EP2247306B1 EP2247306B1 EP09710780.9A EP09710780A EP2247306B1 EP 2247306 B1 EP2247306 B1 EP 2247306B1 EP 09710780 A EP09710780 A EP 09710780A EP 2247306 B1 EP2247306 B1 EP 2247306B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tumor
- cst
- cells
- cell
- associated antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 166
- 230000002163 immunogen Effects 0.000 title claims description 105
- 210000004881 tumor cell Anatomy 0.000 title description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 248
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 202
- 108091007433 antigens Proteins 0.000 claims description 118
- 102000036639 antigens Human genes 0.000 claims description 118
- 239000000427 antigen Substances 0.000 claims description 117
- 150000001413 amino acids Chemical class 0.000 claims description 103
- 210000004027 cell Anatomy 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 42
- 102000043131 MHC class II family Human genes 0.000 claims description 36
- 108091054438 MHC class II family Proteins 0.000 claims description 36
- 230000001472 cytotoxic effect Effects 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 23
- 231100000433 cytotoxic Toxicity 0.000 claims description 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 15
- 102100021410 Heat shock 70 kDa protein 14 Human genes 0.000 claims description 9
- 101001041756 Homo sapiens Heat shock 70 kDa protein 14 Proteins 0.000 claims description 6
- 108700020796 Oncogene Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000052575 Proto-Oncogene Human genes 0.000 claims description 5
- 108700020978 Proto-Oncogene Proteins 0.000 claims description 5
- 108010067390 Viral Proteins Proteins 0.000 claims description 5
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 109
- 229940024606 amino acid Drugs 0.000 description 94
- 235000001014 amino acid Nutrition 0.000 description 93
- 108090000623 proteins and genes Proteins 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 210000003289 regulatory T cell Anatomy 0.000 description 24
- 230000001603 reducing effect Effects 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000008685 targeting Effects 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 210000000612 antigen-presenting cell Anatomy 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 13
- 108010002687 Survivin Proteins 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108091008875 B cell receptors Proteins 0.000 description 10
- 210000001163 endosome Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 102000006311 Cyclin D1 Human genes 0.000 description 9
- 108010058546 Cyclin D1 Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 150000002894 organic compounds Chemical class 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 7
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 150000001945 cysteines Chemical class 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- -1 nucleoredoxins Proteins 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 108010058432 Chaperonin 60 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010366 cell biology technique Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000002468 redox effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003019 stabilising effect Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- DVQCNGKZAMNXCR-BYPYZUCNSA-N (2s)-3-methyl-2-(sulfanylamino)butanoic acid Chemical compound CC(C)[C@H](NS)C(O)=O DVQCNGKZAMNXCR-BYPYZUCNSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108010030351 DEC-205 receptor Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710106383 Disulfide bond formation protein B Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 description 1
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010041384 HLA-DPA antigen Proteins 0.000 description 1
- 108010045483 HLA-DPB1 antigen Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 108700042652 LMP-2 Proteins 0.000 description 1
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710116318 Probable disulfide formation protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 108060008225 Thiolase Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000014725 late viral mRNA transcription Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007921 solubility assay Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Definitions
- the present invention relates to immunogenic peptides and their use in (immune)therapies for the eradication of tumours and tumour cells and prevention of tumour relapses.
- tumours express antigens which may serve as a target or therapy.
- antigens can be broadly divided into:
- tumour-associated antigens or derivatives or adoptive transfer of cells expanded in vitro with such tumour-associated antigens could in theory be of interest for the therapy of tumours.
- CD4+ T cells can help in providing help to B cells to produce specific antibodies and that the production of IFN-gamma by Th1 CD4+ T cells could reduce angiogenesis. More recently, the requirement of CD4+ T cells as a source of IL-2 to help CD8+ T cells to acquire full maturation has been described. Höhn et al. (1999) J. Immunol.
- WO02095051 discloses peptides from human MAGE which comprise a cysteine in a DxxC or CxxF motif. Schultz et al.
- WO2008/017517 discloses peptides comprising a redox motif and an MHC class II epitope from allergens and autoantigens such as HSP60.
- Desmetz et al. (2008) J. Prot. Res. 7, 3830-3837 identifies HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma
- WO2009/042215 discloses that when dendritic cells are loaded with a tumor antigen and cultured in interleukin-15 (IL- 15), Treg activity that is specific for the tumor antigen is reduced.
- IL- 15 interleukin-15
- Treg activity results in an increase in anti-tumor immune response.
- Carlier et al. (2012) PlosOne 7, e45366 further characterises cytolytic cells generated by peptides with a redox motif sequence and a MHC Class II T cell epitope.
- One aspect of the present invention relates to isolated immunogenic peptides of between 12 and 50 amino acids comprising (i) an MHC class II restricted T-cell epitope from a tumor-associated antigen and immediately adjacent thereto or separated therefrom with a linker of up to 7 amino acids (ii) a C-(X)2-[CST] or [CST]-(X)2-C redox motif, for use in the treatment of a tumor expressing said tumor-associated antigen or for use in the treatment or prevention of a relapse of a tumor expressing said tumor-associated antigen.
- tumour-associated antigen may be chosen from oncogenes, proto-oncogenes, viral proteins, surviving factors or clonotypic determinants.
- the C-(X)2-[CST] or [CST]-(X)2-C motif in said immunogenic peptide may be adjacent to said T-cell epitope, or be separated from said T-cell epitope by a linker of up to 7 amino acids.
- said linker consists of at most 7 amino acids.
- said C-(X)2-[CST] or [CST]-(X)2-C motif does not naturally occur within a region of 11 amino acids N-terminally or C-terminally of the T-cell epitope in the tumour-associated antigen.
- said C-(X)2-[CST] or [CST]-(X)2-C motif is positioned N-terminally of the T-cell epitope.
- at least one X in said [CST]-(X)2-[CST] motif is Gly, Ala, Ser or Thr;
- at least one X in the C-(X)2-[CST] or [CST]-(X)2-C motif is His or Pro.
- at least one C in the C-(X)2-[CST] or [CST]-(X)2-C motif is methylated.
- the immunogenic peptide further comprises an endosomal targeting sequence.
- Any of the above immunogenic peptides may be produced by chemical synthesis or by recombinant expression.
- a further aspect of the invention relates to in vitro methods for obtaining a population of tumour associated antigen specific CD4+ T cells which are cytotoxic against cells presenting an MHC class II restricted T cell epitope of said tumor associated antigen, the method comprising the steps of:
- Another aspect of the invention relates to isolated immunogenic peptides of between 12 and 50 amino acids comprising a MHC class II restricted T-cell epitope from a tumor associated antigen and, immediately adjacent to said T-cell epitope or separated from said T-cell epitope by a linker of up to 7 amino acids, a C-(X)2-[CST] or [CST]-(X)2-C redox motif, with the proviso that the tumor associated antigen is not a viral protein, and with the proviso that said tumour associated antigen is not heat shock protein HSP60.
- Another aspect of the invention relates to isolated immunogenic peptides of between 12 and 50 amino acids comprising (i) MHC class II restricted a T-cell epitope from a tumor B-cell idiotype and immediately adjacent thereto or separated therefrom with a linker of up to 7 amino acids (ii) a C-(X)2-[CST] or [CST]-(X)2-C redox motif, for use in the treatment or prevention of said B-cell tumor or for use in the treatment or prevention of a relapse of said B- cell tumor.
- a further aspect of the invention relates to isolated immunogenic peptides of between 12 and 50 amino acids comprising (i) an MHC class II restricted T-cell epitope from a tumor T-cell CDR3 and immediately adjacent thereto or separated therefrom with a linker of up to 7 amino acids (ii) a C-(X)2-[CST] or [CST]-(X)2-C redox motif, for use in the treatment or prevention of said T-cell tumor or for use in the treatment or prevention of a relapse of said T-cell tumor.
- peptide when used herein refers to a molecule comprising an amino acid sequence of between 2 and 200 amino acids, connected by peptide bonds, but which can in a particular embodiment comprise non-amino acid structures (like for example a linking organic compound).
- Peptides according to the invention can contain any of the conventional 20 amino acids or modified versions thereof, or can contain non-naturally occurring amino acids
- epitope when used herein refers to one or several portions (which may define a conformational epitope) of a protein or factor which is/are specifically recognised and bound by an antibody or a portion thereof (Fab', Fab2', etc.) or a receptor presented at the cell surface of a B or T cell lymphocyte, and which is able, by said binding, to induce an immune response.
- antigen when used herein refers to a structure of a macromolecule comprising one or more hapten(s) and/or comprising T cell epitopes.
- said macromolecule is a protein or peptide (with or without polysaccharides) or made of proteic composition and comprises one or more epitopes; said macromolecule can herein alternatively be referred to as "antigenic protein” or “antigenic peptide”.
- tumour-associated antigen refers to any protein, peptide or antigen associated with (carried by, produced by, secreted by, etc) a tumour or tumour cell(s).
- Tumour-associated antigens may be (nearly) exclusively associated with a tumour or tumour cell(s) and not with healthy normal cells or may be overexpressed (e.g., 10 times, 100 times, 1000 times or more) in a tumour or tumour cell(s) compared to healthy normal cells. More particularly a tumour-associated antigen is an antigen capable of being presented (in processed form) by MHC determinants of the tumour cell.
- tumours associated antigens are likely to be associated only with tumours or tumour cells expressing MHC molecules.
- T cell epitope or "T-cell epitope” in the context of the present invention refers to a dominant, sub-dominant or minor T cell epitope, i.e., a part of an antigenic protein or factor that is specifically recognized and bound by a receptor at the cell surface of a T lymphocyte. Whether an epitope is dominant, sub-dominant or minor depends on the immune reaction elicited against the epitope. Dominance depends on the frequency at which such epitopes are recognised by T cells and able to activate them, among all the possible T cell epitopes of a protein.
- the T cell epitope is an epitope bound by MHC class II molecules.
- MHC refers to "major histocompatibility antigen”.
- HLA human leukocyte antigen
- HLA human leukocyte antigen
- HLA-A HLA-A
- HLA-B HLA-C
- HLA-DPA HLA-DPB1
- HLA-DQA HLA-DRA
- HLA-DRB HLA-DRB1
- MHC class I molecules are made of a single polymorphic chain containing 3 domains (alpha 1, 2 and 3), which associates with beta 2 microglobulin at cell surface.
- Class II molecules are made of 2 polymorphic chains, each containing 2 chains (alpha 1 and 2, and beta 1 and 2).
- Class I MHC molecules are expressed on virtually all nucleated cells. Peptide fragments presented in the context of class I MHC molecules are recognized by CD8+ T lymphocytes (cytotoxic T lymphocytes or CTLs). CD8+ T lymphocytes frequently mature into cytotoxic effectors which can lyse cells bearing the stimulating antigen. Class II MHC molecules are expressed primarily on activated lymphocytes and antigen-presenting cells. CD4+ T lymphocytes (helper T lymphocytes or HTLs) are activated with recognition of a unique peptide fragment presented by a class II MHC molecule, usually found on an antigen presenting cell like a macrophage or dendritic cell. CD4+ T lymphocytes proliferate and secrete cytokines that either support an antibody-mediated response through the production of IL-4 and IL-10 or support a cell-mediated response through the production of IL-2 and IFN-gamma.
- Functional HLAs are characterised by a deep binding groove to which endogenous as well as foreign, potentially antigenic peptides bind.
- the groove is further characterised by a well-defined shape and physico-chemical properties.
- HLA class I binding sites are closed, in that the peptide termini are pinned down into the ends of the groove. They are also involved in a network of hydrogen bonds with conserved HLA residues. In view of these restraints, the length of bound peptides is limited to 8-10 residues. However, it has been demonstrated that peptides of up to 12 amino acid residues are also capable of binding HLA class I.
- Superposition of the structures of different HLA complexes confirmed a general mode of binding wherein peptides adopt a relatively linear, extended conformation.
- class II sites are open at both ends. This allows peptides to extend from the actual region of binding, thereby "hanging out” at both ends.
- Class II HLAs can therefore bind peptide ligands of variable length, ranging from 9 to more than 25 amino acid residues. Similar to HLA class I, the affinity of a class II ligand is determined by a "constant” and a “variable” component. The constant part again results from a network of hydrogen bonds formed between conserved residues in the HLA class II groove and the main-chain of a bound peptide. However, this hydrogen bond pattern is not confined to the N-and C-terminal residues of the peptide but distributed over the whole chain.
- the latter is important because it restricts the conformation of complexed peptides to a strictly linear mode of binding. This is common for all class II allotypes.
- the second component determining the binding affinity of a peptide is variable due to certain positions of polymorphism within class II binding sites. Different allotypes form different complementary pockets within the groove, thereby accounting for subtype-dependent selection of peptides, or specificity. Importantly, the constraints on the amino acid residues held within class II pockets are in general "softer" than for class I. There is much more cross reactivity of peptides among different HLA class II allotypes.
- the sequence of the +/- 9 amino acids of an MHC class II T cell epitope that fit in the groove of the MHC II molecule are usually numbered P1 to P9. Additional amino acids N-terminal of the epitope are numbered P-1, P-2 and so on, amino acids C-terminal of the epitope are numbered P+ 1, P+2 and so on.
- organic compound having a reducing activity when used herein refers to particular amino acid sequences, capable of reducing disulfide bonds in proteins.
- An alternatively used term is "redox motif".
- therapeutically effective amo unt refers to an amount of the peptide of the invention or derivative thereof, which produces the desired therapeutic or preventive effect in a patient.
- the therapeutically effective amount is the amount of the peptide of the invention or derivative thereof, which will lead to an improvement or restoration of the normal physiological situation.
- when used to therapeutically treat a mammal affected by an immune disorder it is a daily amount peptide/kg body weight of the said mammal.
- the amount of naked DNA or viral vectors is adjusted to ensure the local production of the relevant dosage of the peptide of the invention, derivative or homologue thereof.
- naturally when used herein referring to a sequence relates to the fact that the sequence is identical to a naturally occurring sequence or is identical to part of such naturally occurring sequence.
- artificial refers to a sequence which as such does not occur in nature. Unless otherwise specified the terms natural and artificial thus exclusively relate to a particular amino acid (or nucleotide) sequence (e.g.
- an artificial sequence is obtained from a natural sequence by limited modifications such as changing one or more amino acids within the naturally occurring sequence or by adding amino acids N- or C-terminally of a naturally occurring sequence.
- Amino acids are referred to herein with their full name, their three-letter abbreviation or their one letter abbreviation.
- Repetition of an identical element within a motif can be indicated by placing behind that element a numerical value or a numerical range between parentheses.
- X(2) corresponds to X-X
- X(2, 4) corresponds to X-X or X-X-X or X-XX- X
- A(3) corresponds to A-A-A.
- homologue when used herein with reference to the epitopes used in the context of the invention, refer to molecules having at least 50%, at least 70%, at least 80%, at least 90%, at least 95% or at least 98% amino acid sequence identity with the naturally occurring epitope, thereby maintaining the ability of the epitope to bind an antibody or cell surface receptor of a B and/or T cell.
- homologues of an epitope correspond to the natural epitope modified in at most three, more particularly in at most two, most particularly in one amino acid.
- derivative when used herein with reference to the peptides of the invention refers to molecules which contain at least the peptide active portion (i.e. capable of eliciting cytolytic CD4+ T cell activity) and, in addition thereto comprises a complementary portion which can have different purposes such as stabilising the peptides or altering the pharmacokinetic or pharmacodynamic properties of the peptide.
- sequence identity of two sequences when used herein relates to the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the sequences, when the two sequences are aligned.
- sequence identity is from 70% to 80%, from 81 % to 85%, from 86% to 90%, from 91 % to 95%, from 96% to 100%, or 100%.
- peptide-encoding polynucleotide (or nucleic acid) and “polynucleotide (or nucleic acid) encoding peptide” when used herein refer to a nucleotide sequence, which, when expressed in an appropriate environment, results in the generation of the relevant peptide sequence or a derivative or homologue thereof.
- polynucleotides or nucleic acids include the normal sequences encoding the peptide, as well as derivatives and fragments of these nucleic acids capable of expressing a peptide with the required activity.
- the nucleic acid encoding the peptides according to the invention or fragment thereof is a sequence encoding the peptide or fragment thereof originating from a mammal or corresponding to a mammalian, most particularly a human peptide fragment.
- the present invention provides strategies for immunotherapy of tumour or tumour cell(s) or tumour relapses using compounds comprising a T-cell epitope derived from a tumour-associated antigen to which a motif with thioreductase activity (or shortly: redox motif) is attached. These compounds elicit tumour-associated antigen-specific CD4+ T-cells with strong capacity to induce apoptosis of tumour cells. These cytotoxic CD4+ T-cells cells can be elicited in vivo by active immunisation with these compounds or can be expanded in vitro ( ex vivo ) for adoptive transfer into tumour-bearing hosts.
- Isolated immunogenic peptides for use in the treatment of a tumour or for the prevention of a tumour relapse in a patient are disclosed. More particularly, the use of at least one isolated immunogenic peptide comprising (i) a T-cell epitope derived from a tumour-associated antigen and (ii) a C-(X)2-[CST] or [CST]-(X)2-C motif, for the manufacture of a medicament for treating a tumour or for preventing or treating a tumour relapse.
- At least one isolated immunogenic peptide comprising (i) a T-cell epitope derived from a tumour-associated antigen and (ii) a C-(X)2-[CST] or [CST]-(X)2-C motif, for the manufacture of a medicament is used for inducing CD4+ regulatory T cells which are cytotoxic to cells presenting said tumour-associated antigen.
- the subject or recipient receiving said immunogenic peptide is a mammal, in particular a (non-human) primate or a human.
- tumour-associated antigen may be chosen from oncogenes, proto-oncogenes, viral proteins, surviving factors or clonotypic/idiotypic determinants. Such antigens are known and accepted in the art.
- the first oncogenes associated with tumours were described for melanomas.
- the MAGE (melanoma-associated gene) products were shown to be spontaneously expressed by tumour cells in the context of MHC class I determinants, and as such, recognised by CDS+ cytolytic T cells.
- MAGE-derived antigens, such as MAGE-3 are also expressed in MHC class II determinants and CD4+ specific T cells have been cloned from melanoma patients ( Schutz et al.
- Peptides presented by MHC class II determinants are known in the art. Other examples include the gp100 antigen expressed by the P815 mastocytoma and by melanoma cells ( Lapointe (2001) J. Immunol. 167: 4758-4764 ; Cochlovius et al. (1999) Int. J. Cancer, 83: 547-554 ). Proto-oncogenes include a number of polypeptides and proteins which are preferentially expressed in tumours cells, and only minimally in healthy tissues.
- Cyclin D1 is cell cycle regulator which is involved in the G1 to S transition. High expression of cyclin D1 has been demonstrated in renal cell carcinoma, parathyroid carcinomas and multiple myeloma. A peptide encompassing residues 198 to 212 has been shown to carry a T cell epitope recognised in the context of MHC class II determinants ( Dengiel et al. (2004) Eur. J. of Immunol. 34: 3644-3651 ).
- Survivin is one example of a factor inhibiting apoptosis, thereby conferring an expansion advantage to survivin-expressing cells.
- Survivin is aberrantly expressed in human cancers of epithelial and hematopoietic origins and not expressed in healthy adult tissues except the thymus, testis and placenta, and in growth-hormone stimulated hematopoietic progenitors and endothelial cells.
- survivin-specific CD8+ T cells are detectable in blood of melanoma patients.
- Survivin is expressed by a broad variety of malignant cell lines, including renal carcinoma, breast cancer, and multiple myeloma, but also in acute myeloid leukemia, and in acute and chronic lymphoid leukemia ( Schmidt (2003) Blood 102: 571-576 ).
- Other examples on inhibitors of apoptosis are Bcl2 and spi6.
- Idiotypic determinants are presented by B cells in follicular lymphomas, multiple myeloma and some forms of leukemia, and by T cell lymphomas and some T cell leukemias. Idiotypic determinants are part of the antigen-specific receptor of either the B cell receptor (BCR) or the T cell receptor (TCR). Such determinants are essentially encoded by hypervariable regions of the receptor, corresponding to complementarity-determining regions (CDR) of either the VH or VL regions in B cells, or the CDR3 of the beta chain in T cells. As receptors are created by the random rearrangement of genes, they are unique to each individual.
- BCR B cell receptor
- TCR T cell receptor
- CDR complementarity-determining regions
- MHC class II determinants Peptides derived from idiotypic determinants are presented in MHC class II determinants ( Baskar et al. (2004) J. Clin. Invest.113: 1498-1510 ). Some tumours are associated with expression of virus-derived antigens. Thus, some forms of Hodgkin disease express antigens from the Epstein-Barr virus (EBV). Such antigens are expressed in both class I and class II determinants. CDS+ cytolytic T cells specific for EBV antigens can eliminate Hodgkin lymphoma cells ( Bollard et al. (2004) J. Exp. Med. 200: 1623-1633 ). Antigenic determinants such as LMP-1 and LMP-2 are presented by MHC class II determinants.
- EBV Epstein-Barr virus
- a minimum requirement for the cytotoxic CD4+ T-cells to be activated is to recognise a cognate tumour-associated antigen-derived epitope presented by MHC class II determinants, leading to apoptosis of the APC.
- MHC class II determinants by tumour cells is likely to be much more frequent than previously thought.
- malignant cells derived from the hematopoietic lineages and cells derived from endothelium or epithelium progenitors express class II determinants.
- expression of such determinants can be induced by inflammatory conditions that often prevail in tumours, as a result of the production of cytokines such as IFN-gamma or TNF-alpha by host cells.
- tumour-associated antigen exists in a given tumour or tumour cell. It is therefore anticipated that combination of two or more immunogenic peptides may be used for the treatment of a tumour or for the treatment or prevention of a tumour relapse.
- the one or more immunogenic peptides can be replaced by CD4+ regulatory T-cells (Tregs) primed with the immunogenic peptide(s) (i.e., adoptive cell transfer), or can be replaced by a nucleotide sequence encoding the immunogenic peptide(s) (e.g. in the form of naked DNA or a viral vector to be administered to an individual instead of the immunogenic peptide).
- Tregs CD4+ regulatory T-cells primed with the immunogenic peptide(s)
- a nucleotide sequence encoding the immunogenic peptide(s) e.g. in the form of naked DNA or a viral vector to be administered to an individual instead of the immunogenic peptide.
- both active immunisation with immunogenic peptides and adoptive cell transfer of in vitro expanded Tregs can be envisaged for antigens which are associated with tumours and not with normal cells, namely oncogenes such as MAGE, idiotypic determinants and perhaps some virus proteins.
- oncogenes such as MAGE, idiotypic determinants and perhaps some virus proteins.
- adoptive cell transfer may be the preferred option.
- target tumour cells by gene therapy, so as to express a given immunogenic peptide according to the invention only in tumour cells.
- any tumour antigen can be used as starting point for designing an immunogenic peptide according to the invention.
- a combination of multiple immunogenic peptides i.e. more than 1 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more), can be used in the above described applications.
- the present invention is based upon the finding that an immunogenic peptide, comprising a T cell epitope derived from a tumour-associated antigen and a peptide sequence, having reducing activity is capable of generating a population of CD4+ regulatory T cells, which have a cytotoxic effect on tumour-associated antigen presenting cells.
- immunogenic peptides comprise at least one T-cell epitope of a tumour-associated antigen with a potential to trigger an immune reaction, coupled to an organic compound having a reducing activity, namely a thioreductase sequence motif.
- the T cell epitope and the thioreductase sequence motif are optionally separated by a linker sequence.
- the immunogenic peptide additionally comprises an endosome targeting sequence (e.g. late endosomal targeting sequence) and/or additional "flanking" sequences.
- the immunogenic peptides of the invention can be schematically represented as A-L-B or B-L-A, wherein A represents a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction, L represents a linker and B represents an organic compound having a reducing activity.
- the reducing activity of an organic compound can be assayed for its ability to reduce a sulfhydryl group such as in the insulin solubility assay known in the art, wherein the solubility of insulin is altered upon reduction, or with a fluorescence-labelled insulin.
- the reducing organic compound may be coupled at the amino-terminus side of the T-cell epitope or at the carboxy-terminus of the T-cell epitope.
- the organic compound with reducing activity is a peptide sequence.
- Peptide fragments with reducing activity are encountered in thioreductases which are small disulfide reducing enzymes including glutaredoxins, nucleoredoxins, thioredoxins and other thiol/disulfide oxidoreductases They exert reducing activity for disulfide bonds on proteins (such as enzymes) through redox active cysteines within conserved active domain consensus sequences: C-X(2)-C, C-X(2)-S, C-X(2)-T, S-X(2)-C, T-X(2)-C ( Fomenko et al. (2003) Biochemistry 42, 11214-11225 ), in which X stands for any amino acid.
- Such domains are also found in larger proteins such as protein disulfide isomerase (PDI) and phosphoinositide-specific phospholipase C.
- PDI protein disulfide isomerase
- immunogenic peptides according to the present invention comprise as redox motif the thioreductase sequence motif [C]-X(2)-[CST] or [CST]-X(2)-[C], in a further embodiment thereto, motif is positioned N-terminally of the T-cell epitope.
- motif such a tetrapeptide will be referred to as "the motif”.
- peptides of the invention contain the sequence motif [C]-X(2)-[CS] or [CS]-X(2)[C].
- peptides contain the sequence motif C-X(2)-S, S-X(2)-C or C-X(2)-C.
- the immunogenic peptides of the present invention can be made by chemical synthesis, which allows the incorporation of non-natural amino acids.
- C represents either cysteine or another amino acids with a thiol group such as mercaptovaline, homocysteine or other natural or non-natural amino acids with a thiol function.
- the cysteines present in the motif should not occur as part of a cystine disulfide bridge.
- the motif may comprise modified cysteines such as methylated cysteine, which is converted into cysteine with free thiol groups in vivo.
- either of the amino acids X in the [C]-X(2)-[CST] or [CST]-X(2)-[C] motif of the immunogenic peptides of the invention can be any natural amino acid, including S, C, or T or can be a non-natural amino acid.
- X is an amino acid with a small side chain such as Gly, Ala, Ser or Thr.
- X is not an amino acid with a bulky side chain such as Tyr.
- at least one X in the C-X(2)-[CST] or [CST]-X(2)-[C] motif is His or Pro.
- the motif is located such that, when the epitope fits into the MHC groove, the motif remains outside of the MHC binding groove.
- the motif is placed either immediately adjacent to the epitope sequence within the peptide, or is separated from the T cell epitope by a linker.
- the linker comprises an amino acid sequence of 7 amino acids or less.
- the linker comprises 1, 2, 3, or 4 amino acids.
- a linker may comprise 6, 8 or 10 amino acids. Typical amino acids used in linkers are serine and threonine.
- Example of peptides with linkers in accordance with the present invention are CXXC-G-epitope (SEQ ID NO:9), CXXC-GG-epitope (SEQ ID NO:10), CXXC-SSS-epitope (SEQ ID NO:11), CXXC-SGSG-epitope (SEQ ID NO:12) and the like.
- the immunogenic peptides of the present invention can further comprise additional short amino acid sequences N or C-terminally of the (artificial) sequence comprising the T cell epitope and the reducing compound (motif). Such an amino acid sequence is generally referred to herein as a 'flanking sequence'.
- a flanking sequence can be positioned N- and/or C-terminally of the redox motif and/or of the T-cell epitope in the immunogenic peptide.
- a flanking sequence can be present between the epitope and an endosomal targeting sequence and/or between the reducing compound (e.g. motif) and an endosomal targeting sequence. More particularly a flanking sequence is a sequence of up to 7 amino acids, or of in between 1 and 7 amino acids, such as a sequence of 2 amino acids.
- the redox motif in the immunogenic peptide is located N-terminally from the epitope.
- the redox motif present in the immunogenic peptide contains one cysteine
- this cysteine is present in the motif in the position most remote from the epitope, thus the motif occurs as C-X(2)-[ST] or C-X(2)-S N-terminally of the epitope or occurs as [ST]-X(2)-C or S-X(2)C carboxy-terminally of the epitope.
- immunogenic peptides comprising one epitope sequence and a motif sequence.
- the motif occurs several times (1, 2, 3, 4 or even more times) in the peptide, for example as repeats of the motif which can be spaced from each other by one or more amino acids (e.g. CXXC X CXXC X CXXC; SEQ ID NO:13), as repeats which are adjacent to each other (CXXC CXXC CXXC; SEQ ID NO:14) or as repeats which overlap with each other CXXCXXCXC (SEQ ID NO:15) or CXCCXCCXCC (SEQ ID NO:16)).
- one or more motifs are provided at both the N and the C terminus of the T cell epitope sequence.
- Other variations envisaged for the immunogenic peptides of the present invention include peptides containing repeats of a T cell epitope sequence or multiple different T-cell epitopes wherein each epitope is preceded and/or followed by the motif (e.g. repeats of "motif-epitope” or repeats of "motif-epitope-motif").
- the motifs can all have the same sequence but this is not obligatory. It is noted that repetitive sequences of peptides which comprise an epitope which in itself comprises the motif will also result in a sequence comprising both the 'epitope' and a 'motif'. In such peptides, the motif within one epitope sequence functions as a motif outside a second epitope sequence.
- the immunogenic peptides of the present invention comprise only one T cell epitope.
- the immunogenic peptides according to the invention comprise, in addition to a reducing compound/motif, a T cell epitope derived from a tumour-associated antigen.
- a T cell epitope in a protein sequence can be identified by functional assays and/or one or more in silico prediction assays.
- the amino acids in a T cell epitope sequence are numbered according to their position in the binding groove of the MHC proteins.
- the T-cell epitope present within the peptides of the invention consists of between 8 and 25 amino acids, yet more particularly of between 8 and 16 amino acids, yet most particularly consists of 8, 9, 10, 11, 12, 13, 14, 15 or 16 amino acids.
- the T cell epitope consists of a sequence of 9 amino acids.
- the T-cell epitope is an epitope, which is presented to T cells by MHC-class II molecules.
- the T cell epitope sequence is an epitope sequence which fits into the cleft of an MHC II protein, more particularly a nonapeptide fitting into the MHC II cleft.
- the T cell epitope of the immunogenic peptides of the invention can correspond either to a natural epitope sequence of a protein or can be a modified version thereof, provided the modified T cell epitope retains its ability to bind within the MHC cleft, similar to the natural T cell epitope sequence.
- the modified T cell epitope can have the same binding affinity for the MHC protein as the natural epitope, but can also have a lowered affinity.
- the binding affinity of the modified peptide is no less than 10-fold less than the original peptide, more particularly no less than 5 times less. It is a finding of the present invention that the peptides of the present invention have a stabilising effect on protein complexes. Accordingly, the stabilising effect of the peptide-MHC complex compensates for the lowered affinity of the modified epitope for the MHC molecule.
- the immunogenic peptides of the invention further comprise an amino acid sequence (or another organic compound) facilitating uptake of the peptide into (late) endosomes for processing and presentation within MHC class II determinants.
- the late endosome targeting is mediated by signals present in the cytoplasmic tail of proteins and correspond to well-identified peptide motifs such as the dileucine-based [DE]XXXL[LI] (SEQ ID NO:17) or DXXLL (SEQ ID NO:18) motif (e.g. DXXXLL; SEQ ID NO:19), the tyrosine-based YXX ⁇ motif or the so-called acidic cluster motif.
- the symbol ⁇ represents amino acid residues with a bulky hydrophobic side chains such as Phe, Tyr and Trp.
- the late endosome targeting sequences allow for processing and efficient presentation of the antigen-derived T cell epitope by MHC-class II molecules.
- Such endosomal targeting sequences are contained, for example, within the gp75 protein ( Vijayasaradhi et al. (1995) J Cell Biol 130, 807-820 ), the human CD3 gamma protein, the HLA-BM ⁇ ( Copier et al. (1996) J. Immunol. 157, 1017-1027 ), the cytoplasmic tail of the DEC205 receptor ( Mahnke et al. (2000) J Cell Biol 151, 673-683 ).
- sequence can be that of a subdominant or minor T cell epitope from a protein, which facilitates uptake in late endosome without overcoming the T cell response towards the tumour-associated antigen -derived T cell epitope.
- the immunogenic peptides of the invention can be generated by coupling a reducing compound, more particularly a reducing motif as described herein, N-terminally or C-terminally to a T-cell epitope of the tumour-associated antigen (either directly adjacent thereto or separated by a linker).
- a reducing compound more particularly a reducing motif as described herein
- the T cell epitope sequence of the immunogenic peptide and/or the redox motif can be modified and/or one or more flanking sequences and/or a targeting sequence can be introduced (or modified), compared to the naturally occurring T-cell epitope sequence.
- the resulting sequence of the immunogenic peptide will in most cases differ from the sequence of the tumour-associated antigen protein of interest.
- the immunogenic peptides of the invention are peptides with an 'artificial', non-naturally occurring sequence.
- the immunogenic peptides of the invention can vary substantially in length, e.g. from about 12-13 amino acids (a T-cell epitope of 8-9 amino acids and the 4-amino acid redox motif) to up to 50 amino acids.
- an immunogenic peptide according to the invention may comprise an endosomal targeting sequence of 40 amino acids, a flanking sequence of about 2 amino acids, a motif as described herein of 4 amino acids, a linker of 4 amino acids and a T cell epitope peptide of 9 amino acids.
- the immunogenic peptides of the invention consist of between 12 amino acids and 20 up to 25, 30, or 50 amino acids. In a more particular embodiment, the peptides consist of between 10 and 20 amino acids.
- the length of the immunogenic peptide comprising the epitope and motif optionally connected by a linker is 18 amino acids or less, e.g., 12, 13, 14, 15, 16, 17, 18 or 19 amino acids.
- the immunogenic peptides of the invention comprise a reducing motif as described herein linked to a T cell epitope sequence.
- the T-cell epitopes are derived from tumour-associated antigens which do not comprise within their native natural sequence an amino acid sequence with redox properties within a sequence of 11 amino acids N- or C- terminally adjacent to the T-cell epitope of interest.
- the invention encompasses generating immunogenic peptides from tumour-associated antigens which do not comprise a sequence selected from C-X(2)-S, S-X(2)-C, C-X(2)-C, S-X(2)-S, C-X(2)-T, T-X(2)-C within a sequence of 11 amino acids N- or C-terminally adjacent to the epitope sequence.
- the present invention provides immunogenic peptides of tumour-associated antigens which do not comprise the above-described amino acid sequences with redox properties within their sequence.
- the immunogenic peptides of the invention are peptides comprising T cell epitopes which T cell epitopes do not comprise an amino acid sequence with redox properties within their natural sequence.
- a T cell epitope binding to the MHC cleft may comprise a redox motif such as described herein within its epitope sequence; the immunogenic peptides according to the invention comprising such a T-cell epitope must further comprise another redox motif coupled (adjacent of separated by a linker) N- or C-terminally to the epitope such that the attached motif can ensure the reducing activity (contrary to the motif present in the epitope, which is buried within the cleft).
- Another aspect of the present invention relates to methods for generating immunogenic peptides of the present invention described herein.
- Such methods include the identification of T-cell epitopes in a tumour-associated antigen of interest; ways for in vitro and in silico identification of T-cell epitopes are amply known in the art and some aspects are elaborated upon hereafter.
- methods according to the invention further include the generation of immunogenic peptides of the invention (including the identified T-cell epitope and a redox motif (with or without linker(s), flanking sequence(s) or endosomal targeting sequence)).
- the generated immunogenic peptides may be assessed for the capability to induce tumour-associated antigen-specific CD4+ regulatory T cells which are cytotoxic for cells presenting (parts of) the tumour-associated antigen of interest.
- Immunogenic peptides according to the invention are generated starting from T cell epitope(s) of the tumour-associated antigen(s) of interest.
- the T-cell epitope used may be a dominant T-cell epitope.
- the identification and selection of a T-cell epitope from a tumour-associated antigen, for use in the context of the present invention is known to a person skilled in the art. For instance, peptide sequences isolated from a tumour-associated antigen are tested by, for example, T cell biology techniques, to determine whether the peptide sequences elicit a T cell response. Those peptide sequences found to elicit a T cell response are defined as having T cell stimulating activity.
- Human T cell stimulating activity can further be tested by culturing T cells obtained from an individual sensitised to a tumour-associated antigen with a peptide/epitope derived from the tumour-associated antigen and determining whether proliferation of T cells occurs in response to the peptide/epitope as measured, e.g., by cellular uptake of tritiated thymidine.
- Stimulation indices for responses by T cells to peptides/epitopes can be calculated as the maximum CPM in response to a peptide/epitope divided by the control CPM.
- Non-natural (or modified) T-cell epitopes can further optionally be tested for their binding affinity to MHC class II molecules.
- the binding of non-natural (or modified) T-cell epitopes to MHC class II molecules can be performed in different ways. For instance, soluble HLA class II molecules are obtained by lysis of cells homozygous for a given class II molecule. The latter is purified by affinity chromatography.
- Soluble class II molecules are incubated with a biotin-labelled reference peptide produced according to its strong binding affinity for that class II molecule. Peptides to be assessed for class II binding are then incubated at different concentrations and their capacity to displace the reference peptide from its class II binding is calculated by addition of neutravidin. Methods can be found in for instance Texier et al., (2000) J. Immunology 164, 3177-3184 ).
- the immunogenic peptides of the invention have a mean T cell stimulation index of greater than or equal to 2.0. An immunogenic peptide having a T cell stimulation index of greater than or equal to 2.0 is considered useful as a prophylactic or therapeutic agent.
- immunogenic peptides according to the invention have a mean T cell stimulation index of at least 2.5, at least 3.5, at least 4.0, or even at least 5.0.
- such peptides typically have a positivity index (P. I.) of at least about 100, at least 150, at least about 200 or at least about 250.
- the positivity index for a peptide is determined by multiplying the mean T cell stimulation index by the percent of individuals, in a population of individuals sensitive to a tumour-associated antigen (e. g., at least 9 individuals, at least 16 individuals or at least 29 or 30, or even more), who have T cells that respond to the peptide (thus corresponding to the SI multiplied by the promiscuous nature of the peptide/epitope).
- the positivity index represents both the strength of a T cell response to a peptide (S.I.) and the frequency of a T cell response to a peptide in a population of individuals sensitive to a tumour-associated antigen.
- a peptide having T cell stimulating activity and thus comprising at least one T cell epitope as determined by T cell biology techniques is modified by addition or deletion of amino acid residues at either the N- or C-terminus of the peptide and tested to determine a change in T cell reactivity to the modified peptide.
- T cell biology techniques If two or more peptides which share an area of overlap in the native protein sequence are found to have human T cell stimulating activity, as determined by T cell biology techniques, additional peptides can be produced comprising all or a portion of such peptides and these additional peptides can be tested by a similar procedure. Following this technique, peptides are selected and produced recombinantly or synthetically. T cell epitopes or peptides are selected based on various factors, including the strength of the T cell response to the peptide/epitope (e.g., stimulation index) and the frequency of the T cell response to the peptide in a population of individuals.
- stimulation index the strength of the T cell response to the peptide/epitope
- the frequency of the T cell response to the peptide in a population of individuals e.g., stimulation index
- Candidate antigens can be screened by one or more in vitro algorithms to identify a T cell epitope sequence within an antigenic protein. Suitable algorithms are described for example in Zhang et al. (2005) Nucleic Acids Res 33, W180-W183 (PREDBALB); Salomon & Flower (2006) BMC Bioinformatics 7, 501 (MHCBN); Schuler et al. (2007) Methods Mol. Biol. 409, 75-93 (SYFPEITHI); Donnes & Kohlbacher (2006) Nucleic Acids Res. 34, W194-W197 (SVMHC); Kolaskar & Tongaonkar (1990) FEBS Lett. 276, 172-174 and Guan et al. (2003) Appl Bioinformatics 2, 63-66 (MHCPred). More particularly, such algorithms allow the prediction within an antigenic protein of one or more nonapeptide sequences which will fit into the groove of an MHC II molecule.
- the immunogenic peptides of the invention can be produced by recombinant expression in, e.g., bacterial cells (e.g. Escherichia coli ), yeast cells (e.g., Pichia species, Hansenula species, Saccharomyces or Schizosaccharomyces species), insect cells (e.g. from Spodoptera frugiperda or Trichoplusia ni ), plant cells or mammalian cells (e.g., CHO, COS cells).
- bacterial cells e.g. Escherichia coli
- yeast cells e.g., Pichia species, Hansenula species, Saccharomyces or Schizosaccharomyces species
- insect cells e.g. from Spodoptera frugiperda or Trichoplusia ni
- plant cells or mammalian cells e.g., CHO, COS cells.
- mammalian cells e.g., CHO, COS cells
- Recombinantly produced immunogenic peptides of the invention can be derived from a larger precursor protein, e.g., via enzymatic cleavage of enzyme cleavage sites inserted adjacent to the N and/or C-terminus of the immunogenic peptide, followed by suitable purification.
- the immunogenic peptides of the invention can be prepared by chemical peptide synthesis, wherein peptides are prepared by coupling the different amino acids to each other.
- Chemical synthesis is particularly suitable for the inclusion of e.g. D-amino acids, amino acids with non-naturally occurring side chains or natural amino acids with modified side chains such as methylated cysteine.
- Chemical peptide synthesis methods are well described and peptides can be ordered from companies such as Applied Biosystems and other companies.
- Peptide synthesis can be performed as either solid phase peptide synthesis (SPPS) or contrary to solution phase peptide synthesis.
- SPPS solid phase peptide synthesis
- SPPS The best-known SPPS methods are t-Boc and Fmoc solid phase chemistry which is amply known to the skilled person.
- peptides can be linked to each other to form longer peptides using a ligation strategy (chemoselective coupling of two unprotected peptide fragments) as originally described by Kent ( Schnolzer & Kent (1992) Int. J. Pept. Protein Res. 40, 180-193 ) and reviewed for example in Tam et al. (2001) Biopolymers 60, 194-205 .
- This provides the tremendous potential to achieve protein synthesis which is beyond the scope of SPPS.
- Many proteins with the size of 100-300 residues have been synthesised successfully by this method.
- Synthetic peptides have continued to play an ever-increasing crucial role in the research fields of biochemistry, pharmacology, neurobiology, enzymology and molecular biology because of the enormous advances in the SPPS.
- the present invention provides in vitro methods for generating tumour-associated antigen-specific cytotoxic T cells (Tregs or CD4+ regulatory T-cells) either in vivo or in vitro ( ex vivo ).
- T cells are cytotoxic towards any presenting a tumour-associated antigen and are obtainable as a population.
- the invention extends to such (populations of) tumour-associated antigen cytotoxic Tregs obtainable by the herein described in vitro methods.
- methods which comprise the isolation of peripheral blood cells, the stimulation of the population in vitro by contacting an immunogenic peptide according to the invention with the isolated peripheral blood cells, and the expansion of the stimulated population, more particularly in the presence of IL-2.
- the methods according to the invention have the advantage that higher numbers of Tregs are produced and that the Tregs can be generated which are specific for the tumour-associated antigen (by using a peptide comprising an antigen-specific epitope).
- tumour-associated antigen-specific cytotoxic T cells may be obtained by incubation in the presence of APCs presenting a tumour-associated antigen-specific immunogenic peptide according to the invention after transduction or transfection of the APCs with a genetic construct capable of driving expression of such immunogenic peptide.
- APCs may in fact themselves be administered to a subject in need to trigger in vivo in said subject the induction of the beneficial subset of cytotoxic CD4+ T-cells.
- Tregs can be generated in vivo, i.e. by the administration of an immunogenic peptide provided herein to a subject, and collection of the Tregs generated in vivo.
- tumour-associated antigen-specific regulatory T cells obtainable by the above methods are of particular interest for use in the manufacture of a medicament for treating a tumour or for preventing or treating a tumour relapse, i.e., for any of the above-described uses of the immunogenic peptides of the invention, said peptides can be replaced by said tumour-associated antigen-specific Tregs.
- Both the use of allogeneic and autogeneic cells is envisaged.
- Any method comprising the administration of said tumour-associated antigen-specific Tregs to a subject in need i.e., for treating a tumour or for preventing or treating a tumour relapse
- Tregs are crucial in immunoregulation and have great therapeutic potential.
- the efficacy of Treg-based immunotherapy depends on the Ag specificity of the regulatory T cells.
- the use of Ag-specific Treg as opposed to polyclonal expanded Treg reduces the total number of Treg necessary for therapy.
- the present invention also relates to nucleic acid sequences encoding the immunogenic peptides of the present invention and methods for their use, e.g., for recombinant expression or in gene therapy.
- said nucleic acid sequences are capable of expressing an immunogenic peptides of the invention.
- immunogenic peptides of the invention may indeed be administered to a subject in need by using any suitable gene therapy method.
- immunisation with an immunogenic peptide of the invention may be combined with adoptive transfer of (a population of) Tregs specific for said immunogenic peptide and/or with gene therapy.
- said immunisation, adoptive cell transfer and gene therapy can be used concurrently, or sequentially in any possible combination.
- recombinant nucleic acid molecules encoding the immunogenic peptides can be used as naked DNA or in liposomes or other lipid systems for delivery to target cells.
- Other methods for the direct transfer of plasmid DNA into cells are well known to those skilled in the art for use in human gene therapy and involve targeting the DNA to receptors on cells by complexing the plasmid DNA to proteins.
- gene transfer can be performed by simply injecting minute amounts of DNA into the nucleus of a cell, through a process of microinjection. Once recombinant genes are introduced into a cell, they can be recognised by the cells normal mechanisms for transcription and translation, and a gene product will be expressed. Other methods have also been attempted for introducing DNA into larger numbers of cells.
- transfection wherein DNA is precipitated with calcium phosphate and taken into cells by pinocytosis
- electroporation wherein cells are exposed to large voltage pulses to introduce holes into the membrane
- lipofection/liposome fusion wherein DNA is packed into lipophilic vesicles which fuse with a target cell
- particle bombardment using DNA bound to small projectiles.
- Another method for introducing DNA into cells is to couple the DNA to chemically modified proteins. Adenovirus proteins are capable of destabilizing endosomes and enhancing the uptake of DNA into cells.
- Adeno-associated virus vectors may also be used for gene delivery into vascular cells.
- gene transfer means the process of introducing a foreign nucleic acid molecule into a cell, which is commonly performed to enable the expression of a particular product encoded by the gene.
- the said product may include a protein, polypeptide, anti-sense DNA or RNA, or enzymatically active RNA. Gene transfer can be performed in cultured cells or by direct administration into mammals.
- a vector comprising a nucleic acid molecule sequence encoding an immunogenic peptide according to the invention.
- the vector is generated such that the nucleic acid molecule sequence is expressed only in a specific tissue. Methods of achieving tissue-specific gene expression are well known in the art, e.g., by placing the sequence encoding an immunogenic peptide of the invention under control of a promoter, which directs expression of the peptide specifically in one or more tissue(s) or organ(s).
- Expression vectors derived from viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, RNA viruses or bovine papilloma virus may be used for delivery of nucleotide sequences (e.g., cDNA) encoding peptides, homologues or derivatives thereof according to the invention into the targeted tissues or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors containing such coding sequences. Alternatively, engineered cells containing a nucleic acid molecule coding for an immunogenic peptide according to the invention may be used in gene therapy.
- viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, RNA viruses or bovine papilloma virus.
- the appropriate dosage of the nucleic acid can be determined based on the amount of peptide expressed as a result of the introduced nucleic acid.
- the medicament of the invention is usually, but not necessarily, a (pharmaceutical) formulation comprising as active ingredient at least one of the immunogenic peptides of the invention, a (population of) Tregs specific for said immunogenic peptide or a gene therapeutic vector capable of expressing said immunogenic peptide.
- a (pharmaceutically acceptable) diluent, carrier or adjuvant Apart from the active ingredient(s), such formulation will comprise at least one of a (pharmaceutically acceptable) diluent, carrier or adjuvant.
- pharmaceutically acceptable compounds can be found in, e.g., a Pharmacopeia handbook (e.g. US-, European- or International Pharmacopeia).
- the medicament or pharmaceutical composition of the invention normally comprises a (prophylactically or therapeutically) effective amount of the active ingredient(s) wherein the effectiveness is relative to the condition or disorder to be prevented or treated.
- the pharmaceutical compositions of the invention are vaccines for prophylactic or therapeutic application.
- the medicament or pharmaceutical composition of the invention may need to be administered to a subject in need as part of a prophylactic or therapeutic regimen comprising multiple administrations of said medicament or composition. Said multiple administrations usual occur sequentially and the time-interval between two administrations can vary and will be adjusted to the nature of the active ingredient and the nature of the condition to be prevented or treated.
- the amount of active ingredient given to a subject in need in a single administration can also vary and will depend on factors such as the physical status of the subject (e.g.,weight, age), the status of the condition to be prevented or treated, and the experience of the treating doctor, physician or nurse
- adjuvants refers for instance to physiological saline solutions.
- adjuvant usually refers to a pharmacological or immunological agent that modifies (preferably increases) the effect of other agents (e.g., drugs, vaccines) while having few if any direct effects when given by themselves.
- agents e.g., drugs, vaccines
- adjuvant aluminium hydroxide alum
- many other adjuvants are known in the art and can be used provided they facilitate peptide presentation in MHC-class II presentation and T cell activation.
- pharmaceutically acceptable carrier means any material or substance with which the active ingredient is formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness. They include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like. Additional ingredients may be included in order to control the duration of action of the active ingredient in the composition.
- the pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e.
- compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, suspensions, ointments, creams, tablets, pellets or powders.
- Suitable pharmaceutical carriers for use in said pharmaceutical compositions and their formulation are well known to those skilled in the art, and there is no particular restriction to their selection within the present invention. They may also include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e.
- compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, coating and/or grinding the active ingredients, in a one-step or multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents. They may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 ⁇ m, namely for the manufacture of microcapsules for controlled or sustained release of the active ingredients.
- Immunogenic peptides, homologues or derivatives thereof according to the invention may be administered by any route appropriate to the condition to be prevented or treated and appropriate for the compounds, here the immunogenic proteins to be administered.
- Possible routes include regional, systemic, oral (solid form or inhalation), rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intraarterial, intrathecal and epidural).
- the preferred route of administration may vary with for example the condition of the recipient or with the condition to be prevented or treated.
- formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- a further aspect of the invention relates to isolated immunogenic peptides as described in the claims, comprising a T-cell epitope from a tumour-associated non- viral antigen other than HSP60 and, adjacent to said T-cell epitope or separated from said T-cell epitope by a linker, a C-(X)2-[CST] or [CST]-(X)2-C motif.
- the epitope is an epitope whereby the tumour associated antigen does not naturally comprise within a sequence of 11 amino acids N- or C-terminally adjacent to said epitope, a redox motif.
- tumour associated antigens for which immunogenic peptides are envisaged are mentioned below.
- An idiotype is made of the ensemble of antigenic determinants carried by the variable part of antibodies and, as described above, these determinants are reiterated in BCR (corresponding to CDRs) and TCR (corresponding to CDR3).
- BCR of a B-cell and the antibodies secreted by the same B-cell share idiotypic determinants.
- parts of the BCR are processed together with the antigen and are presented by MHC class II determinants.
- the B-cell receptor is most often directed towards an antigen of undetermined specificity (for example the MGUS syndrome: monoclonal gammopathy of unknown specificity).
- tumours or tumour cells comprises the induction (by immunisation and/or gene therapy) of CD4+ regulatory T-cells cytotoxic towards tumour BCR T-cell epitopes (or an idiotope thereof; together referred to hereinafter as tumour B-cell idiotype) or T-cell CDR3 T-cell epitope, and/or adoptive transfer of said cytotoxic CD4+ regulatory T-cells.
- tumour B-cell BCR T-cell epitopes or an idiotope thereof
- tumour T-cell CDR3 T-cell epitope modified by attaching a redox motif thereto are capable of inducing CD4+ T-cells that can drive said tumour B-cells or tumour T-cells into apoptosis.
- the invention relates to isolated immunogenic peptides of between 12 and 50 amino acids comprising (i) MHC class II restricted a T-cell epitope from a tumor B-cell idiotype and immediately adjacent thereto or separated therefrom with a linker of up to 7 amino acids (ii) a C-(X)2-[CST] or [CST]-(X)2-C redox motif, for use in the treatment or prevention of said B-cell tumor or for use in the treatment or prevention of a relapse of said B- cell tumor.
- the invention relates to isolated immunogenic peptides of between 12 and 50 amino acids comprising (i) an MHC class II restricted T-cell epitope from a tumor T-cell CDR3 and immediately adjacent thereto or separated therefrom with a linker of up to 7 amino acids (ii) a [CST]-(X)2-C or [CST]-(X)2-C redox motif, for use in the treatment or prevention of said T-cell tumor or for use in the treatment or prevention of a relapse of said T-cell tumor.
- kits for treating patients suffering from a tumour expressing a viral antigen comprise, administering to the patient, an immunogenic peptide according to the invention comprising a T-cell epitope against the viral antigen and a redox motif as described herein.
- the viral antigen is an antigen of a virus selected from the group consisting of herpes viruses, C-type viruses and B-type RNA mammary tumour viruses.
- Cytotoxic regulatory CD4+ T cells are elicited by in vivo immunisation with a peptide comprising a melanoma-associated antigen (MAGE-31 T cell epitope to which a thioreductase consensus sequence is added
- C57BI/6 mice (group 1) are immunised with 25 ⁇ g of a peptide containing a (natural) T cell epitope of MAGE-3 by 3 footpath injections in CFA/IFA made at a fortnight interval.
- the sequence of the (natural) T-cell epitope corresponds to amino acids 258 to 266 of MAGE-3, namely: YRQVPGSDP (SEQ ID NO:1).
- a second group of C57BI/6 mice (group 2) are immunised using the same protocol with the peptide of SEQ ID NO:1to which a consensus motif exhibiting thioreductase activity (or shortly: redox motif) was added at the amino-terminal end, namely: CHGC YRQVPGSDP (SEQ ID NO:2; redox motif underlined; modified T-cell epitope)
- mice Ten days after the last immunisation, the spleens of all mice are recovered and CD4+ T cells are prepared by sorting on magnetic beads.
- Spleen adherent cells prepared from na ⁇ ve C57BI/6 mice are used as antigen-presenting cells (APC).
- APC antigen-presenting cells
- CD4+ T cells obtained from either group 1 or group 2 mice are added to the population of A PCs and co-cultured for 24 h at 37°C. Cells are then recovered and incubated with a fluorescent-labelled anti-CD11 c antibody and with FITC-labelled annexin V as a marker of apoptosis. Finally, cells are analysed by Facs analysis.
- Cytotoxic regulatory CD4+ T cells are elicited by in vivo immunisation with a peptide comprising a cyclin 01 T-cell epitope to which a thioreductase consensus sequence is added
- C57BI/6 mice (group 1) are immunised with 25 ⁇ g of a peptide containing a (natural) T-cell epitope of cyclin D1 by 3 footpath injections in CFA/IFA made at a fortnight interval.
- the sequence of the peptide corresponds to amino acids 185 to 193 of cyclin D1, namely: FVALCATDV (SEQ ID NO:3).
- a second group of C57BI/6 mice (group 2) are immunized using the same protocol as above but with peptide of SEQ ID NO:3 to which a consensus motif exhibiting thioreductase activity (or shortly: redox motif) is added at the amino-terminal end, namely: CHGC FVALCATDV (SEQ ID NO:4; redox motif underlined; modified T-cell epitope).
- mice Ten days after the last immunisation, the spleens of all mice are recovered and CD4+ T cells are prepared by sorting on magnetic beads.
- Spleen adherent cells prepared from na ⁇ ve C57BI/6 mice are used as antigen-presenting cells (APC).
- APC antigen-presenting cells
- CD4+ T cells obtained from either group 1 or group 2 mice are added to the population of A PCs and co-cultured for 24 h at 37 °C. Cells are then recovered and incubated with a fluorescent-labelled anti-CD11 c antibody and with FITC-labelled annexin V as a marker of apoptosis. Finally, cells are analysed by Facs analysis.
- Cytotoxic regulatory CD4+ T cells are elicited by in vivo immunisation with a peptide comprising a survivin T cell epitope to which a thioreductase consensus sequence is added
- C57BI/6 mice (group 1) are immunised with 25 ⁇ g of a peptide containing a (natural) T cell epitope of survivin by 3 footpath injections in CFA/IFA made at a fortnight interval.
- the sequence of the peptide corresponds to amino acids 61 to 69 of survivin, namely: FKELEGWEP (SEQ ID NO:5).
- a second group of C57BI/6 mice (group 2) are immunised using the same protocol with peptide of SEQ ID NO:5 to which a consensus motif exhibiting thioreductase activity (or shortly: redox motif) was added at the amino-terminal end, namely: CHGC FKELEGWEP (SEQ ID NO:6; redox motif underlined; modified T-cell epitope).
- mice Ten days after the last immunisation, the spleens of all mice are recovered and CD4+ T cells are prepared by sorting on magnetic beads.
- Spleen adherent cells prepared from na ⁇ ve C57BI/6 mice are used as antigen-presenting cells (APC).
- APC antigen-presenting cells
- CD4+ T cells obtained from either group 1 or group 2 mice are added to the population of A PCs and co-cultured for 24 h at 37 °C. Cells are then recovered and incubated with a fluorescent-labelled anti-CD11 c antibody and with FITC-labelled annexin V as a marker of apoptosis. Finally, cells are analysed by Facs analysis.
- Cytotoxic regulatory CD4+ T cells are elicited by in vivo immunisation with a peptide comprising an Epstein-Barr LMP2 T cell epitope to which a thioreductase consensus sequence is added
- mice (group 1) are immunised with 25 ⁇ g of a peptide containing a (natural) T cell epitope of LMP2 from the Epstein-Barr virus by 3 footpath injections in CFA/IFA made at a fortnight interval.
- the sequence of the peptide corresponds to amino acids 167 to 175 of LMP2, namely: VASSYAAAQ (SEQ ID NO:7).
- a second group of BALB/c mice (group 2) are immunised using the same protocol with peptide of SEQ ID NO:? to which a consensus motif exhibiting thioreductase activity (or shortly: redox motif) is added at the amino-terminal end, namely: CHGC VASSYAAAQ (SEQ ID NO:8; redox motif underlined; modified T-cell epitope).
- mice Ten days after the last immunisation, the spleens of all mice are recovered and CD4+ T cells are prepared by sorting on magnetic beads.
- Spleen adherent cells prepared from na ⁇ ve BALB/c mice are used as antigen-presenting cells (APC).
- APC antigen-presenting cells
- CD4+ T cells obtained from either group 1 or group 2 mice are added to the population of A PCs and co-cultured for 24 h at 37 °C. Cells are then recovered and incubated with a fluorescent-labelled anti-CD11 c antibody and with FITC-labelled annexin V as a marker of apoptosis. Finally, cells are analysed by Facs analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
- Peptide immunogène isolé ayant entre 12 et 50 acides aminés comprenant (i) un épitope de cellule T limité à la classe II du CMH provenant d'un antigène associé à une tumeur et immédiatement adjacent à celui-ci ou séparé de celui-ci par un lieur ayant jusqu'à 7 acides aminés (ii) un motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C, pour utilisation dans le traitement d'une tumeur exprimant ledit antigène associé à une tumeur ou pour utilisation dans le traitement ou la prévention d'une rechute d'une tumeur exprimant ledit antigène associé à une tumeur.
- Peptide selon la revendication 1, pour utilisation selon la revendication 1, dans lequel ledit antigène associé à une tumeur est un oncogène, un proto-oncogène, une protéine virale, un facteur survivant ou un déterminant clonotypique.
- Peptide selon la revendication 1 ou 2, pour utilisation selon la revendication 1, dans lequel ledit motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C ne se produit pas naturellement à l'intérieur d'une région de 11 acides aminés à terminaison N ou C adjacente à l'épitope de cellule T dans ledit antigène associé à une tumeur.
- Peptide selon l'une quelconque des revendications 1 à 3, pour utilisation selon la revendication 1, dans lequel ledit motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C est positionné au niveau de la terminaison N de l'épitope de cellule T.
- Peptide selon l'une quelconque des revendications 1 à 4, pour utilisation selon la revendication 1, dans lequel au moins un X dans ledit motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C est Gly, Ala, Ser ou Thr, ou dans lequel au moins un X dans ledit motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C est His ou Pro, et/ou dans lequel au moins un C dans ledit motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-C(X)2-C est méthylé.
- Procédé in vitro pour obtenir une population de cellules T CD4+ spécifiques à un antigène associé à une tumeur qui sont cytotoxiques contre des cellules présentant un épitope de cellule T limité à la classe II du CMH dudit antigène associé à une tumeur, le procédé comprenant les étapes de :- fourniture de cellules de sang périphérique ;- mise en contact desdites cellules in vitro avec un peptide immunogène ayant entre 12 et 50 acides aminés comprenant (i) un épitope de cellule T limité à la classe II du CMH provenant dudit antigène associé à une tumeur et immédiatement adjacent à celui-ci ou séparé de celui-ci avec un lieur ayant jusqu'à 7 acides aminés (ii) un motif d'oxydo-réduction C-(X)2-[CST] ou [CTS]-(X)2-C, avec la condition que ledit antigène associé à une tumeur n'est pas la protéine de choc thermique HSP60 ;
et- expansion desdites cellules en présence d'IL-2 - Population de cellules T CD4+ spécifiques à un antigène associé à une tumeur qui sont cytotoxiques contre des cellules présentant un épitope de cellule T limité à la classe II du CMH dudit antigène associé à une tumeur, que l'on peut obtenir par le procédé selon la revendication 6, avec la condition que ledit antigène associé à une tumeur n'est pas la protéine de choc thermique HSP60.
- Population de cellules T CD4+ spécifiques à un antigène associé à une tumeur qui sont cytotoxiques contre des cellules présentant un épitope de cellule T limité à la classe II du CMH dudit antigène associé à une tumeur, selon la revendication 7 pour utilisation dans le traitement ou la prévention d'une tumeur exprimant ledit antigène associé à une tumeur ou pour utilisation dans le traitement ou la prévention d'une rechute d'une tumeur exprimant ledit antigène associé à une tumeur.
- Peptide immunogène isolé ayant entre 12 et 50 acides aminés comprenant un épitope de cellule T limité à la classe II du CMH provenant d'un antigène associé à une tumeur et, immédiatement adjacent audit épitope de cellule T ou séparé dudit épitope de cellule T par un lieur ayant jusqu'à 7 acides aminés, un motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C, avec la condition que l'antigène associé à une tumeur n'est pas une protéine virale, et avec la condition que ledit antigène associé à une tumeur n'est pas la protéine de choc thermique HSP60.
- Peptide immunogène isolé ayant entre 12 et 50 acides aminés comprenant (i) un épitope de cellule T limité à la classe II du CMH provenant d'un idiotype de cellule B de tumeur et immédiatement adjacent à celui-ci ou séparé de celui-ci par un lieur ayant jusqu'à 7 acides aminés (ii) un motif d'oxydo-réduction C-(X)2-[CST] ou [CST]-(X)2-C, pour utilisation dans le traitement ou la prévention de ladite tumeur de cellule B ou pour utilisation dans le traitement ou la prévention d'une rechute de ladite tumeur de cellule B.
- Peptide immunogène isolé ayant entre 12 et 50 acides aminés comprenant (i) un épitope de cellule T limité à la classe II du CMH provenant d'une cellule T CDR3 de tumeur et immédiatement adjacent à celui-ci ou séparé de celui-ci par un lieur ayant jusqu'à 7 acides aminés (ii) un motif d'oxydo-réduction [CST]-(X)2-C ou C-(X)2-[CST], pour utilisation dans le traitement ou la prévention de ladite cellule T de tumeur ou pour utilisation dans le traitement ou la prévention d'une rechute de ladite tumeur à cellule T.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13150813.7A EP2626081B1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
EP20130151001 EP2623115A1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
EP09710780.9A EP2247306B1 (fr) | 2008-02-14 | 2009-02-16 | Lutte par voie immunogène contre les tumeurs et cellules tumorales |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08447011 | 2008-02-14 | ||
US3585608P | 2008-03-12 | 2008-03-12 | |
EP09710780.9A EP2247306B1 (fr) | 2008-02-14 | 2009-02-16 | Lutte par voie immunogène contre les tumeurs et cellules tumorales |
PCT/EP2009/051804 WO2009101205A2 (fr) | 2008-02-14 | 2009-02-16 | Lutte par voie immunogène contre les tumeurs et cellules tumorales |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13150813.7A Division-Into EP2626081B1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
EP13150813.7A Division EP2626081B1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
EP20130151001 Division-Into EP2623115A1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2247306A2 EP2247306A2 (fr) | 2010-11-10 |
EP2247306B1 true EP2247306B1 (fr) | 2018-04-18 |
Family
ID=40852363
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09710780.9A Active EP2247306B1 (fr) | 2008-02-14 | 2009-02-16 | Lutte par voie immunogène contre les tumeurs et cellules tumorales |
EP13150813.7A Active EP2626081B1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
EP20130151001 Withdrawn EP2623115A1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13150813.7A Active EP2626081B1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
EP20130151001 Withdrawn EP2623115A1 (fr) | 2008-02-14 | 2009-02-16 | Contrôle immunogène de tumeurs et cellules tumorales |
Country Status (6)
Country | Link |
---|---|
US (2) | US8999346B2 (fr) |
EP (3) | EP2247306B1 (fr) |
AU (1) | AU2009214039B2 (fr) |
CA (1) | CA2715488C (fr) |
ES (2) | ES2676630T3 (fr) |
WO (1) | WO2009101205A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2059256T3 (pl) | 2006-08-11 | 2017-02-28 | Life Sciences Research Partners Vzw | Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych |
ES2676630T3 (es) | 2008-02-14 | 2018-07-23 | Life Sciences Research Partners Vzw | Control inmunogénico de tumores y células tumorales |
EP2245059B1 (fr) | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Lymphocytes t cd4+ présentant des propriétés cytolytiques |
EP2719396B1 (fr) * | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunothérapie ciblant les agents pathogènes intracellulaires |
ES2545885T3 (es) * | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Eliminación de respuestas inmunitarias contra vectores virales |
ES2584430T3 (es) * | 2008-02-14 | 2016-09-27 | Life Sciences Research Partners Vzw | Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles |
AU2008350785B2 (en) * | 2008-02-14 | 2013-10-03 | Katholieke Universiteit Leuven | Immunogenic peptides and their use in transplantation |
CA2820617C (fr) | 2010-11-25 | 2020-01-07 | Imnate Sarl | Peptides immunogenes destines a la prevention et/ou au traitement de maladies infectieuses, de maladies auto-immunes, de reponses immunitaires aux allofacteurs, de maladies allerg iques, de tumeurs, du rejet de greffe, et des reponses immunitaires dirigees contre des vecteurs viraux utilises en therapie genique ou en vaccination genique |
GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) * | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
EP3939606A3 (fr) | 2015-09-25 | 2022-04-20 | ImCyse SA | Composés et procédés améliorés permettant de supprimer des réponses immunitaires à des agents thérapeutiques |
SG11201808710UA (en) | 2016-04-19 | 2018-11-29 | Imcyse Sa | Novel immunogenic cd1d binding peptides |
NZ755744A (en) | 2017-03-09 | 2023-07-28 | Imcyse Sa | Peptides and methods for the treatment of diabetes |
CN112218883A (zh) | 2018-04-26 | 2021-01-12 | 艾吉纳斯公司 | 热休克蛋白结合肽组合物及其使用方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009042215A2 (fr) * | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition de l'activation et de la potentialisation des lymphocytes t régulateurs entraînées par une cellule dendritique de réponses des lymphocytes t spécifiques d'un antigène de tumeur par l'interleukine-15 et un inhibiteur de la kinase map |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
AU579148B2 (en) | 1984-03-09 | 1988-11-17 | Scripps Clinic And Research Foundation | Synthetic hepatitis b virus vaccine including both t cell and b cell determinants |
US4886782A (en) * | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
ES2194836T3 (es) | 1990-09-27 | 2003-12-01 | Tripep Ab | Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana. |
KR100260342B1 (ko) | 1991-10-16 | 2000-07-01 | 스타세이 엘. 첸링 | 더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프 |
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US5589582A (en) * | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
US5824315A (en) | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
US8791237B2 (en) * | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US7157089B1 (en) * | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
WO1999021979A1 (fr) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Vecteurs du papillomavirus humain |
NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
US6656471B1 (en) | 1998-11-17 | 2003-12-02 | Board Of Regents, The University Of Texas System | HIV-specific T-cell induction |
US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
EP2311950A1 (fr) | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Nouveaux épitopes de lymphocytes T restreints de classe II de MHC pour l'antigène de cancer, NY ESO-1 |
GB0006437D0 (en) * | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
EP1294905A1 (fr) * | 2000-06-26 | 2003-03-26 | SmithKline Beecham Biologics SA | Proteines hybrides triples contenant de l'ubiquitine fusionnee entre une thioredoxine et un polypeptide d'interet |
US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
EP1409650B1 (fr) | 2001-05-30 | 2006-04-12 | Fondazione Telethon | Lymphocytes t cd25+cd4+ isoles ex vivo a activite immunosuppressive et utilisations |
US20050107256A1 (en) * | 2001-10-03 | 2005-05-19 | Barnwell Stephen G. | Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
WO2003072731A2 (fr) | 2002-02-21 | 2003-09-04 | Apovia, Inc. | Particules chimeres hbc stabilisees ayant des immunogenes meningoques |
WO2004018667A1 (fr) | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | Peptides et medicaments les contenant |
CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
DE10243666A1 (de) * | 2002-09-20 | 2004-04-01 | Bayer Ag | Dithiocarbaminsäureester |
JP2004147649A (ja) | 2002-10-11 | 2004-05-27 | Kumamoto Technology & Industry Foundation | 頭頚部癌の抗原 |
EP1609107A4 (fr) | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | Procedes d'identification de variants optimaux d'epitopes peptidiques |
US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
EP1687333A2 (fr) | 2003-10-30 | 2006-08-09 | Pharmexa A/S | Procede de regulation negative du facteur de croissance endotheliale vasculaire |
KR20100092031A (ko) | 2004-06-17 | 2010-08-19 | 맨카인드 코포레이션 | 에피토프 유사체 |
JP2008044848A (ja) | 2004-11-30 | 2008-02-28 | Univ Kurume | Hla−a24拘束性腫瘍抗原ペプチド |
US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
WO2007027954A2 (fr) | 2005-08-30 | 2007-03-08 | Children's Hospital & Research Center At Oakland | Methodes pour identifier un epitope de polypeptide, des polypeptides antigenes de chlamydia identifies par ces methodes, et des methodes d'utilisation associees |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
FR2898275B1 (fr) | 2006-03-10 | 2012-12-14 | Genethon | Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire |
WO2007135684A2 (fr) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Procédé de traitement d'auto-immunité anti-cd4 |
PL2059256T3 (pl) * | 2006-08-11 | 2017-02-28 | Life Sciences Research Partners Vzw | Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
ES2545885T3 (es) * | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Eliminación de respuestas inmunitarias contra vectores virales |
ES2584430T3 (es) | 2008-02-14 | 2016-09-27 | Life Sciences Research Partners Vzw | Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles |
EP2245059B1 (fr) | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Lymphocytes t cd4+ présentant des propriétés cytolytiques |
ES2676630T3 (es) | 2008-02-14 | 2018-07-23 | Life Sciences Research Partners Vzw | Control inmunogénico de tumores y células tumorales |
AU2008350785B2 (en) * | 2008-02-14 | 2013-10-03 | Katholieke Universiteit Leuven | Immunogenic peptides and their use in transplantation |
EP2719396B1 (fr) * | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunothérapie ciblant les agents pathogènes intracellulaires |
WO2009101201A2 (fr) | 2008-02-15 | 2009-08-20 | Chemetall Gmbh | Mélanges d'hydrures métalliques et de liquides ioniques et utilisation de ces mélanges |
WO2009106073A2 (fr) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Multimères de mhc dans le diagnostic et le traitement de la borréliose |
KR101022649B1 (ko) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치 |
EP2337795A2 (fr) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
RU2600798C2 (ru) | 2009-04-01 | 2016-10-27 | Юниверсити Оф Майами | Композиции вакцин и способы их применения |
EP2552476B1 (fr) | 2010-03-29 | 2016-12-07 | Centre National De La Recherche Scientifique - Cnrs | Compositions pharmaceutiques comprenant un polypeptide comprenant au moins un motif cxxc et des antigènes hétérologues et leurs utilisations |
CA2820617C (fr) | 2010-11-25 | 2020-01-07 | Imnate Sarl | Peptides immunogenes destines a la prevention et/ou au traitement de maladies infectieuses, de maladies auto-immunes, de reponses immunitaires aux allofacteurs, de maladies allerg iques, de tumeurs, du rejet de greffe, et des reponses immunitaires dirigees contre des vecteurs viraux utilises en therapie genique ou en vaccination genique |
GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
SG11201404943PA (en) | 2012-02-15 | 2014-10-30 | Ecole Polytech | Erythrocyte-binding therapeutics |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
EP3939606A3 (fr) | 2015-09-25 | 2022-04-20 | ImCyse SA | Composés et procédés améliorés permettant de supprimer des réponses immunitaires à des agents thérapeutiques |
-
2009
- 2009-02-16 ES ES09710780.9T patent/ES2676630T3/es active Active
- 2009-02-16 WO PCT/EP2009/051804 patent/WO2009101205A2/fr active Application Filing
- 2009-02-16 EP EP09710780.9A patent/EP2247306B1/fr active Active
- 2009-02-16 ES ES13150813.7T patent/ES2627882T3/es active Active
- 2009-02-16 AU AU2009214039A patent/AU2009214039B2/en active Active
- 2009-02-16 US US12/735,740 patent/US8999346B2/en active Active
- 2009-02-16 EP EP13150813.7A patent/EP2626081B1/fr active Active
- 2009-02-16 EP EP20130151001 patent/EP2623115A1/fr not_active Withdrawn
- 2009-02-16 CA CA2715488A patent/CA2715488C/fr active Active
-
2015
- 2015-01-05 US US14/589,134 patent/US10617748B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009042215A2 (fr) * | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition de l'activation et de la potentialisation des lymphocytes t régulateurs entraînées par une cellule dendritique de réponses des lymphocytes t spécifiques d'un antigène de tumeur par l'interleukine-15 et un inhibiteur de la kinase map |
Non-Patent Citations (3)
Title |
---|
C. DESMETZ ET AL: "Proteomics-Based Identification of HSP60 as a Tumor-Associated Antigen in Early Stage Breast Cancer and Ductal Carcinoma in situ", JOURNAL OF PROTEOME RESEARCH, vol. 7, no. 9, 5 September 2008 (2008-09-05), pages 3830 - 3837, XP055211020, ISSN: 1535-3893, DOI: 10.1021/pr800130d * |
SCHULTZ ERWIN S ET AL: "A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 60, no. 22, 15 November 2000 (2000-11-15), pages 6272 - 6275, XP002212994, ISSN: 0008-5472 * |
VINCENT A CARLIER ET AL: "Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 7, no. 10, E45366, 9 October 2012 (2012-10-09), pages 1 - 16, XP002716287, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0045366 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009101205A2 (fr) | 2009-08-20 |
US10617748B2 (en) | 2020-04-14 |
US20110002903A1 (en) | 2011-01-06 |
AU2009214039A1 (en) | 2009-08-20 |
WO2009101205A3 (fr) | 2009-10-08 |
EP2623115A1 (fr) | 2013-08-07 |
US8999346B2 (en) | 2015-04-07 |
EP2626081A1 (fr) | 2013-08-14 |
ES2627882T3 (es) | 2017-07-31 |
CA2715488C (fr) | 2019-09-24 |
EP2247306A2 (fr) | 2010-11-10 |
AU2009214039B2 (en) | 2013-09-19 |
ES2676630T3 (es) | 2018-07-23 |
EP2626081B1 (fr) | 2017-03-22 |
CA2715488A1 (fr) | 2009-08-20 |
US20150110821A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2247306B1 (fr) | Lutte par voie immunogène contre les tumeurs et cellules tumorales | |
US20240207379A1 (en) | Strategies to prevent and/or treat immune responses to soluble allofactors | |
CA2715484C (fr) | Suppression des reponses immunitaires aux vecteurs viraux | |
EP2719396B1 (fr) | Immunothérapie ciblant les agents pathogènes intracellulaires | |
CA3118620A1 (fr) | Peptides immunogenes dotes de nouveaux motifs d'oxydoreductase | |
IL268874B2 (en) | Peptides and methods for treating diabetes | |
AU2013270496B2 (en) | Immunogenic control of tumours and tumour cells | |
AU2016202443A1 (en) | Immunogenic control of tumours and tumour cells | |
AU2013263773A1 (en) | Elimination of immune responses to viral vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100831 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
17Q | First examination report despatched |
Effective date: 20110111 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN Owner name: LIFE SCIENCES RESEARCH PARTNERS VZW |
|
111L | Licence recorded |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR Free format text: EXCLUSIVE LICENSE Name of requester: IMCYSE S.A., BE Effective date: 20141015 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160216 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20160713 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
111L | Licence recorded |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR Free format text: EXCLUSIVE LICENSE Name of requester: IMCYSE S.A., BE Effective date: 20141015 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: ERGAENZUNG LIZENZEINTRAG: AUSSCHLIESSLICHE LIZENZ |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 989729 Country of ref document: AT Kind code of ref document: T Effective date: 20180515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009051835 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ING. MARCO ZARDI C/O M. ZARDI AND CO. S.A., CH |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2676630 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180723 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180718 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180718 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180719 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 989729 Country of ref document: AT Kind code of ref document: T Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180820 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009051835 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230328 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240220 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240219 Year of fee payment: 16 Ref country code: ES Payment date: 20240325 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240219 Year of fee payment: 16 Ref country code: GB Payment date: 20240219 Year of fee payment: 16 Ref country code: CH Payment date: 20240301 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240228 Year of fee payment: 16 Ref country code: FR Payment date: 20240221 Year of fee payment: 16 Ref country code: BE Payment date: 20240219 Year of fee payment: 16 |